Fiche publication
Date publication
avril 2018
Journal
European journal of cancer (Oxford, England : 1990)
Auteurs
Membres identifiés du Cancéropôle Est :
Dr EYMARD Jean-Christophe
,
Dr SPAETH Dominique
Tous les auteurs :
Thibault C, Eymard JC, Birtle A, Krainer M, Baciarello G, Fléchon A, Le Moulec S, Spaeth D, Laguerre B, Caffo O, Deville JL, Beuzeboc P, Hasbini A, Gross-Goupil M, Helissey C, Bennamoun M, Hardy-Bessard AC, Oudard S
Lien Pubmed
Résumé
Treatment option in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (DOC), cabazitaxel (CABA) and new hormone therapy (NHT) is limited. Rechallenge with DOC is limited because of cumulative toxicities. This study investigated the activity and safety of CABA rechallenge in mCRPC.
Mots clés
Cabazitaxel, Metastatic castration-resistant prostate cancer, Overall survival, Progression-free survival, Rechallenge, Safety, Taxanes
Référence
Eur. J. Cancer. 2018 Apr 7;:
